Neal Ready is Professor of Medicine at Duke University School of Medicine. OpenAlex indexes 308 publications with 32,845 citations (h-index 48); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Neal E. Ready, MD, is Professor of Medicine at Duke University School of Medicine / Duke Cancer Institute. The public record shows 308 publications with 32,845 citations (h-index 48), centered on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 23 companies.
- Most recent indexed publication: 2025 · Clinical cancer research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 124.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- TOP 2301: Neoadjuvant Chemo for NSCLC
Sponsor: Duke University
- A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Sponsor: Alliance Foundation Trials, LLC.
Industry payments
Updated 14 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202516 payments$30,442openpaymentsdata.cms.gov ↗
- TAIHO ONCOLOGY, INC.Program year20251 payment
- Daiichi Sankyo Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
48.8%l-Thyroxine48.8%Levothyroxine Sodium100%Part D≥11 patientsCancer & immunology
20.9%Kinase inhibitor20.9%Tagrisso100%Part D<11 patientsSensory organs
15.1%Corticosteroid15.1%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
65 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.
Clinical cancer research
Clinical Trial2025 - Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.
Journal for immunotherapy of cancer
Clinical Trial2025 - Tumor-Associated Molecules Lead the Way to New Therapies for Small Cell Lung Cancer.
JCO oncology practice
Editorial2025 - Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Journal for immunotherapy of cancer
Clinical Trial2025 - A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
Clinical cancer research
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
lungcancerinitiative.org/leadership-board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungcancerinitiative.org ↗ - Other
livelung.org/post/video-small-cell-lung-cancer-what-s-new-in-treatment-and-research-neal-ready-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →livelung.org ↗ - Other
onclive.com/authors/neal-e-ready-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
- Board Certified
Internal Medicine, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dukehealth.org ↗
Editorial & leadership roles
journal and society appointments- Cadre committee member
CALGB (Cancer and Leukemia Group B) Respiratory Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗ - Leads the clinical research program office for thoracic oncology
Duke Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗ - Board of Directors member and Chair
Scientific Advisory Committee, Lung Cancer Initiative
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lungcancerinitiative.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
- Precision Cancer Medicine and Investigational Therapeutics program
Duke Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukecancerinstitute.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
William Kraus, MD
Duke University School of Medicine
Angeles Secord, MD
Duke University School of Medicine
Virginia Kraus, MD, PhD
Duke University School of Medicine
Robert Mentz, MD
Duke University School of Medicine
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center